Citigroup Downgrades PTC Therapeutics to Neutral, Lowers Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebovitz has downgraded PTC Therapeutics from Buy to Neutral and lowered the price target from $55 to $29.

September 18, 2023 | 8:57 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
PTC Therapeutics has been downgraded by Citigroup from Buy to Neutral, with a lowered price target from $55 to $29.
The downgrade from Buy to Neutral by Citigroup indicates a less optimistic outlook for PTC Therapeutics. The significant reduction in price target from $55 to $29 suggests that the analyst sees less upside potential in the stock, which could negatively impact investor sentiment and put downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100